![]() |
市場調查報告書
商品編碼
1373944
功能服務提供者(FSP)的全球市場預測(截至2027年)Functional Service Providers (FSP) Market Research Report Forecast till 2027 |
在研究期間,全球功能服務提供者 (FSP) 市場規模預計將以 7.49% 的複合年增長率健康成長。
該市場受到多種因素的推動,例如研發企業的擴張、臨床前試驗的增加以及藥物改進中 FSP 外包的增加。
不斷增加的研發活動,尤其是生物製藥和生技公司的研發活動,正在推動全球市場對功能服務提供者 (FSP) 的需求。研究表明,大型生物製藥公司對 FSP 的使用每年以超過 13% 的速度成長。
區域考慮
北美市場形成最大市場,2022年市佔率約41%。這是由於該地區擁有完善的醫療基礎設施、大量的臨床前研究以及 IQVIA(美國)、Parexel(美國)和 Labcorp Memination Improvement(美國)等關鍵參與者。
歐洲市場因技術創新不斷增加、醫療消費增加、慢性病盛行率上升而佔據第二大市場。據 EMA 稱,歐盟成員國在任何特定時間正在進行約 4,000 項臨床試驗。預計到 2022 年,德國將佔據最大的市場份額,而法國將成為歐洲成長最快的市場。
預計2023年至2027年亞太市場發展最快。
該報告研究和分析了全球功能服務提供者(FSP)市場,提供市場動態、區域和細分市場分析、公司概況等。
The Functional Service Providers (FSP) is anticipated to register a healthy CAGR of 7.49% during the review period.
This market is being driven by various elements, including expanding Research and development ventures, the rising number of clinical preliminaries, and the ascent of FSP outsourcing in drug improvement.
Rising Research and development speculations, particularly in the biopharmaceutical and biotechnology businesses, have made a requirement for functional service providers (FSPs) in the worldwide market. Research showed that the utilization of FSPs by enormous biopharmaceutical organizations is developing at a pace of over 13% yearly. These service providers offer staff to biopharmaceutical and biotechnology organizations for their exploration and advancement projects. They give profoundly qualified research partners, information supervisors, concentrate on organizers, clinical screens, and other related staff backing to these organizations.
Moreover, FSPs offer arrangements like preliminary administration, clinical checking, information the executives, factual programming, biostatistics, clinical composition, lifecycle security, and administrative undertakings. The tedious and costly nature of clinical preliminaries and the issues brought about by the high responsibility bring about the rising notoriety of FSPs. These providers save the organization time and lessen functional expenses.
Segment Insights
Segmentation of the global functional service provider market by type includes clinical monitoring, medical publishing, data management, pharmacovigilance, biostatistics/programming, regulatory, and others.
Based on phase, the global functional service provider market has been segmented into clinical trial phase and post-approval phase. Based on applications, the global functional service providers industry has been segmented into biopharmaceutical companies, biotechnology companies, medical device companies, and research centers and hubs. University institutes.
Regional Insights
The North America functional service providers market represented the biggest market with a portion of roughly 41% in 2022, because of the created medical care foundation, countless clinical preliminaries, and the presence of significant central participants in the region like IQVIA (US), Parexel (US), and Labcorp Medication Improvement (US).
Europe functional service supplier market represented the second-biggest market share because of innovation headways, expanding medical care consumption, and expanding predominance of ongoing sicknesses. As per the EMA, around 4,000 clinical preliminaries happen consistently across the European Association (EU) nations. Moreover, the Germany functional service supplier held the biggest market share in 2022, and the France functional service providers is extended be the quickest developing market in the Europe region.
The Asia-Pacific functional service providers market is supposed to be the quickest developing from 2023 to 2027 attributable to high understanding populace, decreased expenses of leading preliminaries, and great administrative arrangements. Also, central members working in the Functional Service Providers (FSP) Market are effectively venturing into Asia-Pacific region. For example, in July 2018, Parexel (US) laid out another auxiliary called Wellbeing Advances in Hong Kong to grow its capacities in the APAC region.
Key Companies in the Functional Service Providers Market are Quanticate International Limited (UK), IQVIA, Inc. (US), BioPoint Inc. (US), Rho, Inc. (US), KPS Life, LLC (US), Parexel International Corporation (US), Laboratory Corporation of America Holdings (US), Wuxi Apptec co., Ltd. (China), Icon Plc (Ireland), and PPD Inc. (US).
TABLE OF CONTENTS